» Articles » PMID: 24164584

History of Myocardial Iron Loading is a Strong Risk Factor for Diabetes Mellitus and Hypogonadism in Adults with β Thalassemia Major

Overview
Journal Eur J Haematol
Specialty Hematology
Date 2013 Oct 30
PMID 24164584
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Endocrinopathies are common complications of transfusional hemosiderosis among patients with β thalassemia major (TM). Previous studies had shown associations between some endocrinopathies and iron overload of the myocardium, liver and/or endocrine organs as assessed by MRI techniques. This retrospective analysis of 92 patients with TM (median age 36 yr) from a tertiary adult thalassemia unit in UK aimed to determine independent risk factors associated with endocrinopathies among these patients. Unlike previous studies, longitudinal data on routine measurements of iron load [worst myocardial and liver T2* values since 1999, worst LIC by MRI-R2 since 2008 and average 10-yr serum ferritin (SF)] up to April 2010 together with demographic features and age of initiating chelation were analyzed for associations with endocrinopathies. The most common endocrinopathies in this cohort were hypogonadism (67%) and diabetes mellitus (DM) (41%), and these were independently associated with myocardial T2* <20 ms (P < 0.001 and P = 0.008, respectively) and increased age (P = 0.002 and P = 0.016, respectively). DM and hypogonadism were independently associated with average SF >1250 μg/L (P = 0.003) and >2000 μg/L (P = 0.047), respectively. DM was also associated with initial detection of abnormal myocardial T2* at an older age (30 yr vs. 24 yr, P = 0.039). An abnormal myocardial T2* may therefore portend the development of DM and hypogonadism in patients with TM.

Citing Articles

Real-world complication burden and disease management paradigms in transfusion-related β-thalassaemia in Greece: Results from ULYSSES, an epidemiological, multicentre, retrospective cross-sectional study.

Kattamis A, Voskaridou E, Delicou S, Klironomos E, Lafiatis I, Petropoulou F EJHaem. 2023; 4(3):569-581.

PMID: 37601860 PMC: 10435690. DOI: 10.1002/jha2.695.


Approach to the management of β thalassemia major associated osteoporosis - A long-standing relationship revisited.

Yavropoulou M, Anastasilakis A, Tzoulis P, Tournis S, Rigatou E, Kassi E Acta Biomed. 2022; 93(5):e2022305.

PMID: 36300213 PMC: 9686151. DOI: 10.23750/abm.v93i5.13668.


Relationship between Serum Ferritin and Outcomes in β-Thalassemia: A Systematic Literature Review.

Shah F, Huey K, Deshpande S, Turner M, Chitnis M, Schiller E J Clin Med. 2022; 11(15).

PMID: 35956067 PMC: 9369259. DOI: 10.3390/jcm11154448.


Screening for glucose dysregulation in β-thalassemia major (β-TM): An update of current evidences and personal experience.

De Sanctis V, Daar S, Soliman A, Tzoulis P, Karimi M, Di Maio S Acta Biomed. 2022; 93(1):e2022158.

PMID: 35315383 PMC: 8972848. DOI: 10.23750/abm.v93i1.12802.


The Influence of Cardiovascular Risk Factors and Hypogonadism on Cardiac Outcomes in an Aging Population of Beta-Thalassemia Patients.

Barbero U, Ajassa M, Gaglioti C, Piga A, Ferrero G, Longo F J Cardiovasc Dev Dis. 2022; 9(1).

PMID: 35050213 PMC: 8781644. DOI: 10.3390/jcdd9010003.